Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Upfront autologous stem cell transplantation for newly diagnosed multiple...

Prof Michele Cavo - Seràgnoli Institute of Hematology, Bologna, Italy

Upfront autologous stem cell transplantation for newly diagnosed multiple myeloma ( Prof Michele Cavo - Seràgnoli Institute of Hematology, Bologna, Italy )

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer?

Prof Charles Ryan and Prof Nick James

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer? ( Prof Charles Ryan and Prof Nick James )

Advanced RET-rearranged NSCLC

Dr Takashi Seto and Dr Kiyotaka Yoh

Advanced RET-rearranged NSCLC ( Dr Takashi Seto and Dr Kiyotaka Yoh )

Global drug pricing: How cost-effective is bevacizumab?

Dr Daniel Goldstein - Emory University, Atlanta, USA

Global drug pricing: How cost-effective is bevacizumab? ( Dr Daniel Goldstein - Emory University, Atlanta, USA )

Update on olaparib in ovarian cancer

Prof Jonathan Ledermann - University College Hospital Medical School, London, UK

Update on olaparib in ovarian cancer ( Prof Jonathan Ledermann - University College Hospital Medical School, London, UK )

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational...

Prof Nick James and Prof Charles Ryan

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational biopsy ( Prof Nick James and Prof Charles Ryan )

Radiotherapy modalities for locally advanced non-small cell lung cancer

Dr Zhongxing Liao - University of Texas MD Anderson Cancer Center, Houston, USA

Radiotherapy modalities for locally advanced non-small cell lung cancer ( Dr Zhongxing Liao - University of Texas MD Anderson Cancer Center, Houston, USA )

First in-human trials of rovalpituzumab for SCLC

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

First in-human trials of rovalpituzumab for SCLC ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )

Impact of precision medicine in refractory malignancies

Prof Maria Schwaederle - University of California, San Diego, USA

$Impact of precision medicine in refractory malignancies ( Prof Maria Schwaederle - University of California, San Diego, USA )$

ASCO 2016: Highlights in prostate cancer from days 3 and 4

Dr Eleni Efstathiou, Prof Kurt Miller, Dr Chris Parker and Prof Stephane Oudard

ASCO 2016: Highlights in prostate cancer from days 3 and 4 ( Dr Eleni Efstathiou, Prof Kurt Miller, Dr Chris Parker and Prof Stephane Oudard )

Large disparities found in BCRA testing across ethnicities

Dr Tuya Pal - Moffitt Cancer Center, Tampa, USA

Large disparities found in BCRA testing across ethnicities ( Dr Tuya Pal - Moffitt Cancer Center, Tampa, USA )

More from ecancer